Alumis’ (ALMS) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Alumis (NASDAQ:ALMS) in a research note issued to investors on Thursday,Benzinga reports. They currently have a $15.00 price objective on the stock, down from their prior price objective of $19.00.

Separately, Oppenheimer started coverage on Alumis in a research report on Thursday, January 30th. They set an “outperform” rating and a $32.00 price target on the stock. Seven analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $26.00.

Alumis Stock Performance

Alumis stock opened at $3.57 on Thursday. Alumis has a fifty-two week low of $3.52 and a fifty-two week high of $13.53. The firm’s fifty day moving average price is $5.76 and its 200-day moving average price is $8.65.

Institutional Trading of Alumis

Institutional investors have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets bought a new stake in shares of Alumis in the 3rd quarter valued at about $27,000. Wells Fargo & Company MN lifted its position in Alumis by 77.1% in the fourth quarter. Wells Fargo & Company MN now owns 8,779 shares of the company’s stock valued at $69,000 after purchasing an additional 3,823 shares during the last quarter. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Alumis during the fourth quarter valued at approximately $79,000. MetLife Investment Management LLC bought a new position in shares of Alumis in the third quarter worth approximately $89,000. Finally, Marshall Wace LLP purchased a new position in shares of Alumis in the fourth quarter worth $108,000.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.